The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM.
Abstract
OBJECTIVE: To assess the oncogenic human papillomavirus (HPV) determination and the cotesting HPV and anal cytology value to detect high-grade anal intraepithelial neoplasia (HGAIN) in a cohort of HIV-MSM. DESIGN AND METHODS: Prospective study of HIV-infected MSM who underwent screening for anal dysplasia. Screening program includes anal cytology, HPV testing, and high-resolution anoscopy (HRA) at each visit. Histological samples were obtained if suspicious lesions were revealed by HRA. Sensitivity and specificity of the different tests were calculated by using histological results of HRA-guided biopsy as the reference test for HGAIN diagnosis. RESULTS: From May 2009 to August 2016, 692 HIV-infected MSM underwent 1827 anal cytologies, 1841 HRA examinations, and 1607 HPV testing. At first screening visit, anal cytology results were abnormal in 418 (60.4%) of 692 patients, and oncogenic HPV genotypes were found in 482 (79.5%) of 606 patients. Anal cytology showed a sensitivity of 89.2% [95% confidence interval (CI); 80.7-94.2] and a specificity of 44.2% (95% CI; 40.2-48.2) to detect HGAIN. Oncogenic HPV testing had 90.4% sensitivity (95% CI; 82-86.8) and 24.4% specificity (95% CI; 20.8-28.3). Cotesting showed a 97.4% sensitivity (95% CI; 91-99.3) and 14% specificity (95% CI; 11.2-17.3). In patients with atypical squamous cells of uncertain significance on cytology, oncogenic HPV testing had 91.3% sensitivity and 28.3% specificity to detect HGAIN. CONCLUSION: Abnormal cytology and oncogenic HPV determination showed similar sensitivity for detecting HGAIN. The two tests used together improved the sensitivity but with lowered specificity. In our opinion, HPV testing does not improve HGAIN detection and should not replace anal cytology as a standard screening test for HIV-infected MSM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrence rates with both provider-applied and patient-applied treatments are high, ranging from approximately 50% at 1 year to 77% after 3 years (1289,1292,1293).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1289]
In the citing paper
“Sensitivity and specificity of anal cytology to detect HSIL are limited (sensitivity 55%–89% and specificity 40%–67%) (1286–1291).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1289]
In the citing paper
“HPV tests (using high-risk HPV types) are not clinically useful for anal cancer screening because of a high prevalence of anal HPV infection among populations at high risk, particularly MSM (1278,1289,1290).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1289]
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Machalek, D. A., Poynten, M., Jin, F., Fairley, C. K., Farnsworth, A., Garland, S. M., Hillman, R. J., Petoumenos, K., Roberts, J. M., Tabrizi, S. N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70080-3 · Cited by 984
Cancer Burden in the HIV-Infected Population in the United States
Shiels, M. S., Pfeiffer, R. M., Gail, M. H., Hall, H. I., Li, J., Chaturvedi, A. K., Bhatia, K. G., Uldrick, T. S., Yarchoan, R., Goedert, J. J., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr076 · Cited by 778
Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Silverberg, M. J., Lau, B., Justice, A. C., Engels, E. A., Gill, M. J., Goedert, J. J., Kirk, G. D., DʼSouza, G., Bosch, R. J., Brooks, J. T., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir1012 · Cited by 518
Anal cancer and cervical cancer screening: Key differences
Darragh, T. M., & Winkler, B. (2010) · Cancer Cytopathology · doi:10.1002/cncy.20126 · Cited by 219
2016 IANS International Guidelines for Practice Standards in the Detection of Anal Cancer Precursors
Hillman, R. J., Cuming, T., Darragh, T. M., et al. (2016) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000256 · Cited by 201
Berry, J. M., Palefsky, J. M., Jay, N., Cheng, S., Darragh, T. M., & Chin-Hong, P. V. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e31819793d9 · Cited by 191
The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening
Salit, I. E., Lytwyn, A., Raboud, J., Sano, M., Chong, S., Diong, C. C., Chapman, W. B., Mahony, J. B., & Tinmouth, J. (2010) · AIDS · doi:10.1097/qad.0b013e328339e592 · Cited by 170
Kitchener, H. C., Canfell, K., Gilham, C., Sargent, A., Roberts, C., Desai, M., & Peto, J. (2014) · Health Technology Assessment · doi:10.3310/hta18230 · Cited by 152
Park, I. U., & Palefsky, J. M. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0090-7 · Cited by 149
Nathan, M., Singh, N., Garrett, N., Hickey, N., Prevost, T. C., & Sheaff, M. T. (2010) · AIDS · doi:10.1097/qad.0b013e328333ab8e · Cited by 116
Cost-effectiveness of screening for anal precancers in HIV-positive men
Lam, J. M., Hoch, J. S., Tinmouth, J., Sano, M., Raboud, J., & Salit, I. E. (2010) · AIDS · doi:10.1097/qad.0b013e3283434594 · Cited by 89
Nahas, C. S. R., Filho, E. V. D. S., Segurado, A. A. C., Genevcius, R. F. F., Gerhard, R., Gutierrez, E. B., Marques, C. F. S., Cecconello, I., & Nahas, S. C. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181b98f36 · Cited by 60
Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM
Burgos, J., Curran, A., Tallada, N., Guelar, A., Navarro, J., Landolfi, S., Villar, J., Casal, M. C., Ribera, E., & Falcó, V. (2015) · AIDS · doi:10.1097/qad.0000000000000603 · Cited by 48
Self-citationSilling, S., Kreuter, A., Hellmich, M., et al. (2012) · Journal of Clinical Virology · doi:10.1016/j.jcv.2011.12.029 · Cited by 45
Human papillomavirus, anal cancer, and screening considerations among HIV-infected individuals.
Cachay, E. R., & Mathews, W. C. (2013) · PubMed · Cited by 43
Goldstone, S. E., Enyinna, C. S., & Davis, T. W. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e31819736aa · Cited by 43
Current Cervical Carcinoma Screening Guidelines
Schlichte, M. J., & Guidry, J. A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050918 · Cited by 43
Anal cancer and screening guidelines for human papillomavirus in men.
Ortoski, R. A., & Kell, C. S. (2011) · PubMed · Cited by 40
Human papillomavirus as a cause of anal cancer and the role of screening
Gosens, K. C. M., Richel, O., & Prins, J. M. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000337 · Cited by 34
Comparison of the performance of anal cytology and cervical cytology as screening tests
Roberts, J. M., & Thurloe, J. K. (2012) · Sexual Health · doi:10.1071/sh11178 · Cited by 31
Cachay, E. R., Agmas, W., & Mathews, W. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038956 · Cited by 27
Mathews, W. C., Agmas, W., & Cachay, E. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024946 · Cited by 27
Hidalgo-Tenorio, C., Rivero-Rodriguez, M., Gil-Anguita, C., Esquivias, J., López-Castro, R., Ramírez-Taboada, J., de Hierro, M. L., López-Ruiz, M. A., Martínez, R. J., & Llaño, J. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123590 · Cited by 25
Anal cytology screening in HIV-positive men who have sex with men: whatʼs new and whatʼs now?
Ho, K. S., & Cranston, R. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328334fe5a · Cited by 20
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Metadata
- Authors
- Burgos, J., Hernández-Losa, J., Landolfi, S., Guelar, A., Dinares, M., Villar, J., Navarro, J., Ribera, E., Falcó, V., & Curran, A.
- Affiliations
- Vall d'Hebron Institut de Recerca (ES)
- Universitat Autònoma de Barcelona (ES)
- Venue
- AIDS
- Published
- 2017-10-23
- Volume
- 31
- Issue
- 16
- Pages
- 2227-2233
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2736847213
- Cited by
- 32
- References
- 25
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 5
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- AIDS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- oncogenic human papillomavirus, high-grade anal intraepithelial neoplasia, HIV-infected men who have sex with men, anal cytology, HPV testing, high-resolution anoscopy, atypical squamous cells of uncertain significance, screening sensitivity and specificity
- MeSH terms
- Adult, Anus Neoplasms, Diagnostic Tests, Routine, Female, Humans, Male, Middle Aged, Prospective Studies, Sensitivity and Specificity, HIV Infections, Homosexuality, Male, Papillomaviridae, Squamous Intraepithelial Lesions of the Cervix
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review